The Formulation and Evaluation of Rasagiline Mesylate Transdermal Patch for Enhanced Topical Delivery
Rasagiline Mesylate Transdermal Patch for Enhanced Topical Delivery
Keywords:Key words: Rasagiline Mesylate, Eudragit L100, PEG 400, Transdermal patch, Parkinson’s disease
Rasagiline mesylate is an irreversible inhibitor of monoamine oxidase (MAO) used for the treatment of the signs and symptoms of idiopathic Parkinson’s disease as initial monotherapy and as adjunct therapy to levodopa. It is a water soluble molecule that undergoes extensive hepatic first pass metabolism resulting to poor bioavailability. The aim of the present study is to formulate and evaluate transdermal delivery system of Rasagiline mesylate. Patches of transdermal delivery systems were formulated by solvent casting technique using different amount of Eudragit L100 as a matrixing material and PEG400 as plasticizer. During preparation of transdermal patches achieving a good tackiness is a most challenging so different formulations were prepared and optimized for finding good tackiness. Among these formulations F12 and F 21 shows optimum results, these formulations are subjected to diffusion studies by using porcine ear skin (80-90um thick) for 24 hrs As the concentration of polymer (Eudragit) increases the permeation was found to decrease. The average amount of drug diffused from F12 and F21 formulation was found to be 25.09µmoles/sq.cm and 21.45µmols/sq.cm respectively.